Added to YB: 2026-03-20
Pitch date: 2026-01-21
IKT [bullish]
Inhibikase Therapeutics, Inc.
+33.52%
current return
Author Info
No bio for this author
Company Info
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Market Cap
$438.8M
Pitch Price
$1.79
Price Target
7.30 (+212%)
Dividend
N/A
EV/EBITDA
-4.23
P/E
-5.57
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Inhibikase Therapeutics, Inc. - $IKT
IKT: Developing gut-masked imatinib prodrug for PAH. Imatinib clinically validated in PAH via multiple RCTs; Novartis discontinued due to brain bleeds (only w/ anticoagulants, no longer used) & limited IP. AVTE's inhaled version failed; IKT doses systemically (should work). 500mg prodrug bioequivalent to 400mg imatinib. GOSS Ph3 readout Feb'26 for seralutinib (inhaled, higher fail risk). IKT trades $550M FD vs GOSS $2B pre-Ph3. PT $7.3/sh assuming 50% PoS, $1.5-3B peak sales (10-20% of 60K US PAH pts). Interim PVR readout ~2.5yrs, 6MWD ~3.5yrs. Risk: GI tox not fully solved, 3yr+ catalyst desert.
Read full article (9 min)